Study identifier:D3466C00001
ClinicalTrials.gov identifier:NCT05138133
EudraCT identifier:2021-002862-42
CTIS identifier:2023-506359-68-00
A Multicentre Randomized Double-Blind Placebo Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients with Active Proliferative Lupus Nephritis
Lupus Nephritis
Phase 3
No
Anifrolumab, Placebo
All
346
Interventional
18 Years - 70 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Sept 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Anifrolumab Solution for intravenous infusion | Drug: Anifrolumab Anifrolumab intravenous infusion (IV) Other Name: Medi-546 |
Placebo Comparator: Placebo Solution for intravenous infusion | Drug: Placebo Placebo intravenous infusion (IV) |